Highlights from ACTRIMS 2026: brain atrophy as a clinical trial endpoint and the FENtrepid trial
Автор: VJNeurology
Загружено: 2026-02-25
Просмотров: 24
Описание:
Le Hanh Hua, MD, Cleveland Clinic, Las Vegas, NV, shares highlights from ACTRIMS 2026. She mentions the discussion surrounding brain atrophy as a surrogate marker for treatment efficacy in clinical trials, and expresses excitement about the FENtrepid trial (NCT04544449) results showing the potential of fenebrutinib for multiple sclerosis treatment. This interview is part of our coverage of the 11th Annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
